Published in Neurobiol Aging on December 07, 2011
Advances in the genetics of Parkinson disease. Nat Rev Neurol (2013) 2.21
Whole exome sequencing of rare variants in EIF4G1 and VPS35 in Parkinson disease. Neurology (2013) 1.78
Suppression of dynamin GTPase decreases α-synuclein uptake by neuronal and oligodendroglial cells: a potent therapeutic target for synucleinopathy. Mol Neurodegener (2012) 1.63
Parkinson's disease-linked mutations in VPS35 induce dopaminergic neurodegeneration. Hum Mol Genet (2014) 1.10
Study of the genetic variability in a Parkinson's Disease gene: EIF4G1. Neurosci Lett (2012) 0.96
The use of next-generation sequencing in movement disorders. Front Genet (2012) 0.94
Genetic perspective on the role of the autophagy-lysosome pathway in Parkinson disease. Autophagy (2015) 0.92
A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants. J Med Genet (2012) 0.90
Recent advances in Parkinson’s disease genetics. J Neurol (2014) 0.84
VPS35 Parkinson's disease phenotype resembles the sporadic disease. J Neural Transm (Vienna) (2014) 0.83
In vivo evidence of pathogenicity of VPS35 mutations in the Drosophila. Mol Brain (2014) 0.82
The role of the retromer complex in aging-related neurodegeneration: a molecular and genomic review. Mol Genet Genomics (2014) 0.81
The pallidopyramidal syndromes: nosology, aetiology and pathogenesis. Curr Opin Neurol (2013) 0.76
VPS35, the Retromer Complex and Parkinson's Disease. J Parkinsons Dis (2017) 0.76
Vacuolar Protein Sorting Genes in Parkinson's Disease: A Re-appraisal of Mutations Detection Rate and Neurobiology of Disease. Front Neurosci (2016) 0.75
The Golgi-localized, gamma ear-containing, ARF-binding (GGA) protein family alters alpha synuclein (α-syn) oligomerization and secretion. Aging (Albany NY) (2017) 0.75
Identification of VPS35 p.D620N mutation-related Parkinson's disease in a Taiwanese family with successful bilateral subthalamic nucleus deep brain stimulation: a case report and literature review. BMC Neurol (2017) 0.75
Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science (1997) 28.30
Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging (2002) 22.40
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature (1998) 21.49
Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science (2004) 15.91
Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron (2004) 14.35
Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron (2004) 13.99
Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science (2002) 9.90
Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet (2011) 9.10
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol (2008) 6.76
Development of the University of Pennsylvania Smell Identification Test: a standardized microencapsulated test of olfactory function. Physiol Behav (1984) 6.50
A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am J Hum Genet (2011) 4.52
Role of the mammalian retromer in sorting of the cation-independent mannose 6-phosphate receptor. J Cell Biol (2004) 4.24
VPS35 mutations in Parkinson disease. Am J Hum Genet (2011) 4.16
Retrograde transport from endosomes to the trans-Golgi network. Nat Rev Mol Cell Biol (2006) 4.14
Retromer. Curr Opin Cell Biol (2008) 3.89
A two-stage meta-analysis identifies several new loci for Parkinson's disease. PLoS Genet (2011) 3.16
Recycle your receptors with retromer. Trends Cell Biol (2005) 3.02
The frequency of idiopathic Parkinson's disease by age, ethnic group, and sex in northern Manhattan, 1988-1993. Am J Epidemiol (1995) 3.00
Sorting by the cytoplasmic domain of the amyloid precursor protein binding receptor SorLA. Mol Cell Biol (2007) 1.70
Olfactory dysfunction in LRRK2 G2019S mutation carriers. Neurology (2011) 1.57
Olfaction in Parkin heterozygotes and compound heterozygotes: the CORE-PD study. Neurology (2010) 1.57
Hyposmia in G2019S LRRK2-related parkinsonism: clinical and pathologic data. Neurology (2008) 1.14
The clinical progression of Parkinson's disease. Parkinsonism Relat Disord (2009) 1.14
Olfaction differentiates parkin disease from early-onset parkinsonism and Parkinson disease. Neurology (2004) 1.06
Olfactory heterogeneity in LRRK2 related Parkinsonism. Mov Disord (2010) 0.87
The use of a color coded probability scale to interpret smell tests in suspected parkinsonism. Mov Disord (2009) 0.86
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet (2009) 15.15
Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron (2004) 13.99
Genotype, haplotype and copy-number variation in worldwide human populations. Nature (2008) 12.40
TREM2 variants in Alzheimer's disease. N Engl J Med (2012) 11.35
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord (2008) 9.52
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet (2010) 8.48
Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord (2007) 6.92
Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis (2006) 5.96
Phenomenology and classification of dystonia: a consensus update. Mov Disord (2013) 4.98
Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region. Nat Genet (2009) 4.61
Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med (2004) 4.56
Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain (2009) 4.01
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord (2007) 3.86
Exome sequencing reveals de novo WDR45 mutations causing a phenotypically distinct, X-linked dominant form of NBIA. Am J Hum Genet (2012) 3.80
SNCA variants are associated with increased risk for multiple system atrophy. Ann Neurol (2009) 3.55
Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord (2007) 3.48
Event-related beta desynchronization in human subthalamic nucleus correlates with motor performance. Brain (2004) 3.36
Dissection of the genetics of Parkinson's disease identifies an additional association 5' of SNCA and multiple associated haplotypes at 17q21. Hum Mol Genet (2010) 3.34
Adaptive deep brain stimulation in advanced Parkinson disease. Ann Neurol (2013) 3.05
DYT16, a novel young-onset dystonia-parkinsonism disorder: identification of a segregating mutation in the stress-response protein PRKRA. Lancet Neurol (2008) 3.03
The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain (2009) 3.03
A common polymorphism in the brain-derived neurotrophic factor gene (BDNF) modulates human cortical plasticity and the response to rTMS. J Physiol (2008) 3.00
Familial frontotemporal dementia with amyotrophic lateral sclerosis and a shared haplotype on chromosome 9p. J Neurol (2010) 2.75
Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. PLoS One (2010) 2.57
Reducing hemorrhagic complications in functional neurosurgery: a large case series and systematic literature review. J Neurosurg (2011) 2.53
Resting oscillatory cortico-subthalamic connectivity in patients with Parkinson's disease. Brain (2010) 2.47
The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts. Neurobiol Dis (2006) 2.42
Gluten ataxia in perspective: epidemiology, genetic susceptibility and clinical characteristics. Brain (2003) 2.41
β-Propeller protein-associated neurodegeneration: a new X-linked dominant disorder with brain iron accumulation. Brain (2013) 2.40
The syndrome of fixed dystonia: an evaluation of 103 patients. Brain (2004) 2.36
Distinguishing SWEDDs patients with asymmetric resting tremor from Parkinson's disease: a clinical and electrophysiological study. Mov Disord (2010) 2.36
Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain (2005) 2.34
A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol (2013) 2.32
The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort. J Neurol Neurosurg Psychiatry (2013) 2.20
Mutations in the gene PRRT2 cause paroxysmal kinesigenic dyskinesia with infantile convulsions. Cell Rep (2011) 2.17
The natural history of treated Parkinson's disease in an incident, community based cohort. J Neurol Neurosurg Psychiatry (2011) 2.08
Identical twins with Leucine rich repeat kinase type 2 mutations discordant for Parkinson's disease. Mov Disord (2012) 2.02
Myoclonic disorders: a practical approach for diagnosis and treatment. Ther Adv Neurol Disord (2011) 2.02
Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease. Ann Neurol (2007) 1.95
Differential regulation of IgG anti-capsular polysaccharide and antiprotein responses to intact Streptococcus pneumoniae in the presence of cognate CD4+ T cell help. J Immunol (2004) 1.90
Intra-operative recordings of local field potentials can help localize the subthalamic nucleus in Parkinson's disease surgery. Exp Neurol (2006) 1.84
Excessive synchronization of basal ganglia neurons at 20 Hz slows movement in Parkinson's disease. Exp Neurol (2007) 1.80
The genetics of Parkinson's syndromes: a critical review. Curr Opin Genet Dev (2009) 1.79
Mutations in ANO3 cause dominant craniocervical dystonia: ion channel implicated in pathogenesis. Am J Hum Genet (2012) 1.78
Targeting amyloid-beta in glaucoma treatment. Proc Natl Acad Sci U S A (2007) 1.77
α-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy? Acta Neuropathol (2013) 1.75
Postural deformities in Parkinson's disease. Lancet Neurol (2011) 1.73
The structure of the tau haplotype in controls and in progressive supranuclear palsy. Hum Mol Genet (2004) 1.72
Globular glial tauopathies (GGT) presenting with motor neuron disease or frontotemporal dementia: an emerging group of 4-repeat tauopathies. Acta Neuropathol (2011) 1.71
Attention to action in Parkinson's disease: impaired effective connectivity among frontal cortical regions. Brain (2002) 1.70
Parkin disease: a clinicopathologic entity? JAMA Neurol (2013) 1.68
Using genome-wide complex trait analysis to quantify 'missing heritability' in Parkinson's disease. Hum Mol Genet (2012) 1.68
Complete screening for glucocerebrosidase mutations in Parkinson disease patients from Portugal. Neurobiol Aging (2007) 1.67
Mitochondrial DNA haplogroup cluster UKJT reduces the risk of PD. Ann Neurol (2005) 1.62
A heterozygous effect for PINK1 mutations in Parkinson's disease? Ann Neurol (2006) 1.61
Argyrophilic grain disease is a sporadic 4-repeat tauopathy. J Neuropathol Exp Neurol (2002) 1.61
Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Ann Neurol (2012) 1.61
Deep brain stimulation in the treatment of chorea. Mov Disord (2011) 1.59
Patient-based outcomes of cervical dystonia: a review of rating scales. Mov Disord (2004) 1.59
Use of next-generation sequencing and other whole-genome strategies to dissect neurological disease. Nat Rev Neurosci (2012) 1.58
Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group. Mov Disord (2007) 1.55
Frequency specific activity in subthalamic nucleus correlates with hand bradykinesia in Parkinson's disease. Exp Neurol (2012) 1.55
Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus. Nat Genet (2012) 1.52
Insights into TREM2 biology by network analysis of human brain gene expression data. Neurobiol Aging (2013) 1.49
Urinary incontinence following deep brain stimulation of the pedunculopontine nucleus. Acta Neurochir (Wien) (2011) 1.46
PRRT2 gene mutations: from paroxysmal dyskinesia to episodic ataxia and hemiplegic migraine. Neurology (2012) 1.44
Olfactory impairment in familial ataxias. J Neurol Neurosurg Psychiatry (2012) 1.44
Opsoclonus myoclonus syndrome associated with GQ1b antibodies. Mov Disord (2012) 1.43
Rapid increase in pertactin-deficient Bordetella pertussis isolates, Australia. Emerg Infect Dis (2014) 1.43
Image-verified deep brain stimulation reduces risk and cost with no apparent impact on efficacy. Mov Disord (2012) 1.42
Streptococcus pneumoniae--a review of carriage, infection, serotype replacement and vaccination. Paediatr Respir Rev (2012) 1.37
Effects of contact location and voltage amplitude on speech and movement in bilateral subthalamic nucleus deep brain stimulation. Mov Disord (2008) 1.37
Adherence to antiparkinson medication in a multicenter European study. Mov Disord (2009) 1.34
Confirmation of functional zones within the human subthalamic nucleus: patterns of connectivity and sub-parcellation using diffusion weighted imaging. Neuroimage (2011) 1.33
Exenatide and the treatment of patients with Parkinson's disease. J Clin Invest (2013) 1.32
NeuroX, a fast and efficient genotyping platform for investigation of neurodegenerative diseases. Neurobiol Aging (2014) 1.32
Complement receptor 1 (CR1) and Alzheimer's disease. Immunobiology (2011) 1.30
Salmonella enterica serovar enteritidis core O polysaccharide conjugated to H:g,m flagellin as a candidate vaccine for protection against invasive infection with S. enteritidis. Infect Immun (2011) 1.29
Effects of low-frequency stimulation of the subthalamic nucleus on movement in Parkinson's disease. Exp Neurol (2007) 1.29
Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson's disease. J Neurol (2009) 1.27
Pertussis in early infancy: disease burden and preventive strategies. Curr Opin Infect Dis (2009) 1.26